Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long-term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)
- Von Hippel-Lindau Disease
- Malignant Neoplasms
At a glance
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- Merck Sharp & Dohme LLC
- Enrolment target
- 450
- Started
- 23 March 2026
- Main results due
- 22 April 2034
- Study sites
- 54
- Registry updated
- 23 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Participants with advanced solid tumors or von Hippel-Lindau-related neoplasms who are participating in belzutifan-containing studies and on active treatment in a belzutifan parent study. Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has an on-going serious adverse event in the parent study, unless no longer hospitalized and considered clinically stable. * Is currently on a dose interruption due to an Adverse Event (AE) in the parent study; once treatment has been resumed in the parent study, the participant is eligible to enroll.
What this study is about
In the sponsor’s own words, from the registry.
Researchers are looking for new ways to treat advanced solid tumors and von Hippel-Lindau (VHL)-related tumors:
* Advanced means the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery * Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids * VHL-related tumors are tumors caused by VHL disease. VHL disease is passed down from parents to children and people with VHL disease have a higher chance of getting certain types of cancer
Researchers want to learn about the long-term effects of a trial medicine called belzutifan. Belzutifan, also called MK-6482, is designed to block a protein that helps tumors grow and survive. This is an extension trial, which means only people who were in certain other belzutifan trials (called parent trials) may be able to join. The goal of this trial is to learn how long people live after they start taking belzutifan.
Study sites(54)
Beth Israel Deaconess Medical Center ( Site 0107)
Boston, Massachusetts, United States
Recruiting
Dana-Farber Cancer Institute ( Site 0105)
Boston, Massachusetts, United States
Recruiting
Karmanos Cancer Center ( Site 0108)
Detroit, Michigan, United States
Recruiting
Hospital of the University of Pennsylvania Perelman Center for Advanced Medicine ( Site 0100)
Philadelphia, Pennsylvania, United States
Recruiting
SCRI Oncology Partners ( Site 7000)
Nashville, Tennessee, United States
Recruiting
START San Antonio ( Site 0104)
San Antonio, Texas, United States
Recruiting
Fred Hutchinson Cancer Center ( Site 0106)
Seattle, Washington, United States
Recruiting
St George Hospital-Oncology Clinical Research Unit ( Site 2701)
Kogarah, New South Wales, Australia
Recruiting
Westmead Hospital ( Site 2703)
Sydney, New South Wales, Australia
Recruiting
Frankston Hospital-Oncology and Haematology ( Site 2705)
Frankston, Victoria, Australia
Recruiting
UZ Leuven ( Site 0900)
Leuven, Vlaams-Brabant, Belgium
Recruiting
BP - A Beneficencia Portuguesa de São Paulo ( Site 0200)
São Paulo, São Paulo, Brazil
Active, not recruiting
Jewish General Hospital ( Site 0001)
Montreal, Quebec, Canada
Active, not recruiting
James Lind Centro de Investigacion del Cancer ( Site 0304)
Temuco, Araucania, Chile
Recruiting
CIDO SpA ( Site 0305)
Temuco, Araucania, Chile
Recruiting
FALP ( Site 0300)
Santiago, Region M. de Santiago, Chile
Recruiting
Oncovida ( Site 0303)
Santiago, Region M. de Santiago, Chile
Recruiting
Bradfordhill ( Site 0301)
Santiago, Region M. de Santiago, Chile
Recruiting
ONCOCENTRO APYS ( Site 0302)
Viña del Mar, Valparaiso, Chile
Recruiting
Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 1000)
Olomouc, Czechia
Recruiting
Herlev and Gentofte Hospital ( Site 1200)
Herlev, Capital Region, Denmark
Recruiting
Tampereen yliopistollinen sairaala ( Site 1305)
Tampere, Pirkanmaa, Finland
Recruiting
Hôpitaux Universitaires de Strasbourg ( Site 1702)
Strasbourg, Bas-Rhin, France
Recruiting
Institut Claudius Regaud ( Site 1703)
Toulouse, Haute-Garonne, France
Recruiting
Gustave Roussy ( Site 1701)
Villejuif, Val-de-Marne, France
Recruiting
Országos Onkológiai Intézet-Urogenitális Tumorok és Klinikai Farmakológiai Osztály ( Site 1501)
Budapest, Hungary
Recruiting
Rambam Health Care Campus ( Site 1600)
Haifa, Israel
Recruiting
Hadassah Medical Center ( Site 1604)
Jerusalem, Israel
Recruiting
Rabin Medical Center ( Site 1602)
Petah Tikva, Israel
Recruiting
Sheba Medical center ( Site 1601)
Ramat Gan, Israel
Recruiting
Sourasky Medical Center ( Site 1603)
Tel Aviv, Israel
Recruiting
Toranomon Hospital ( Site 3100)
Minato, Tokyo, Japan
Recruiting
Kyushu University Hospital ( Site 3101)
Fukuoka, Japan
Recruiting
Tokushima University Hospital ( Site 3102)
Tokushima, Japan
Recruiting
Maastricht Universitair Medisch Centrum - MUMC ( Site 1900)
Maastricht, Limburg, Netherlands
Recruiting
Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 1901)
Amsterdam, North Holland, Netherlands
Recruiting
Isala, locatie Zwolle ( Site 1902)
Zwolle, Overijssel, Netherlands
Recruiting
Auckland City Hospital ( Site 3000)
Auckland, New Zealand
Recruiting
Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 2000)
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Recruiting
N.N. Blokhin NMRCO ( Site 2101)
Moscow, Moscow, Russia
Active, not recruiting
Russian Scientific Center of Radiology and Surgical Technologies ( Site 2100)
Saint Petersburg, Sankt-Peterburg, Russia
Active, not recruiting
Samsung Medical Center ( Site 2902)
Gangnam, Seoul, South Korea
Recruiting
Severance Hospital, Yonsei University Health System ( Site 2901)
Seodaemun-gu, Seoul, South Korea
Recruiting
Asan Medical Center ( Site 2900)
Seoul, South Korea
Recruiting
Hospital Universitari Vall d'Hebron ( Site 2300)
Barcelona, Spain
Recruiting
Hospital Universitario 12 de Octubre ( Site 2301)
Madrid, Spain
Recruiting
Taipei Veterans General Hospital ( Site 2800)
Taipei, Taiwan
Active, not recruiting
ME І.І. Mechnykov Dnipro Regional Clinical Hospital ( Site 2601)
Dnipropetrovsk, Dnipropetrovsk Oblast, Ukraine
Recruiting
CNCE Precarpathian Clinical Oncologic Center ( Site 2600)
Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine
Active, not recruiting
The Beatson West of Scotland Cancer Centre ( Site 2505)
Glasgow, Glasgow City, United Kingdom
Recruiting
St Bartholomew's Hospital ( Site 2500)
London, London, City of, United Kingdom
Recruiting
ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 2502)
London, London, City of, United Kingdom
Recruiting
Imperial College Healthcare NHS Trust, Charing Cross Hospital ( Site 2504)
London, London, City of, United Kingdom
Active, not recruiting
The Christie NHS Foundation Trust ( Site 2501)
Manchester, United Kingdom
Recruiting
Showing 54 of 54 sites. 47 of the 54 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07405164. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me